Pacira Pharmaceuticals CFO Sells $555,500 in Stock (PCRX)
Pacira Pharmaceuticals (NASDAQ:PCRX) CFO James Scibetta sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, December 30th. The stock was sold at an average price of $55.55, for a total transaction of $555,500.00. Following the sale, the chief financial officer now directly owns 5,000 shares of the company’s stock, valued at approximately $277,750. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.
Pacira Pharmaceuticals (NASDAQ:PCRX) traded down 1.69% during mid-day trading on Thursday, hitting $56.52. The stock had a trading volume of 407,170 shares. Pacira Pharmaceuticals has a 52-week low of $17.15 and a 52-week high of $58.22. The stock’s 50-day moving average is $53.24 and its 200-day moving average is $43.37. The company’s market cap is $1.896 billion.
Pacira Pharmaceuticals (NASDAQ:PCRX) last issued its quarterly earnings data on Thursday, October 31st. The company reported ($0.30) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.35) by $0.05. The company had revenue of $23.30 million for the quarter, compared to the consensus estimate of $22.10 million.
PCRX has been the subject of a number of recent research reports. Analysts at Wedbush reiterated a “buy” rating on shares of Pacira Pharmaceuticals in a research note to investors on Monday, November 4th. They now have a $59.00 price target on the stock. Separately, analysts at Jefferies Group raised their price target on shares of Pacira Pharmaceuticals from $58.00 to $60.00 in a research note to investors on Monday, November 4th. They now have a “buy” rating on the stock. Finally, analysts at Barclays raised their price target on shares of Pacira Pharmaceuticals from $56.00 to $60.00 in a research note to investors on Friday, November 1st. They now have an “overweight” rating on the stock. One research analyst has rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $55.20.
Pacira Pharmaceuticals, Inc is a United States-based pharmaceutical company. The Company develops non-opioid products for postsurgical pain control.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.